Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Apr;36(4):879–882. doi: 10.1128/aac.36.4.879

In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

K V Rolston 1, H T Nguyen 1, D H Ho 1, B LeBlanc 1, G P Bodey 1
PMCID: PMC189479  PMID: 1503453

Abstract

The in vitro activity of Ro 23-9424 against bacterial isolates from patients with cancer was compared with those of fleroxacin, ciprofloxacin, cefoperazone, and ceftazidime. Ro 23-9424 inhibited the majority of the members of the family Enterobacteriaceae and all Aeromonas isolates at a concentration of less than or equal to 1.0 micrograms/ml. It was also active against Acinetobacter spp. and Haemophilus influenzae, including beta-lactamase-producing strains. The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients.

Full text

PDF
879

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beskid G., Fallat V., Lipschitz E. R., McGarry D. H., Cleeland R., Chan K., Keith D. D., Unowsky J. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents. Antimicrob Agents Chemother. 1989 Jul;33(7):1072–1077. doi: 10.1128/aac.33.7.1072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P. Antibiotics in patients with neutropenia. Arch Intern Med. 1984 Sep;144(9):1845–1851. [PubMed] [Google Scholar]
  3. Bodey G. P. Infection in cancer patients. A continuing association. Am J Med. 1986 Jul 28;81(1A):11–26. doi: 10.1016/0002-9343(86)90510-3. [DOI] [PubMed] [Google Scholar]
  4. Christenson J. G., Chan K. K., Cleeland R., Dix-Holzknecht B., Farrish H. H., Jr, Patel I. H., Specian A. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals. Antimicrob Agents Chemother. 1990 Oct;34(10):1895–1900. doi: 10.1128/aac.34.10.1895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dekker A. W., Rozenberg-Arska M., Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987 Jan;106(1):7–11. doi: 10.7326/0003-4819-106-1-7. [DOI] [PubMed] [Google Scholar]
  6. Georgopapadakou N. H., Bertasso A., Chan K. K., Chapman J. S., Cleeland R., Cummings L. M., Dix B. A., Keith D. D. Mode of action of the dual-action cephalosporin Ro 23-9424. Antimicrob Agents Chemother. 1989 Jul;33(7):1067–1071. doi: 10.1128/aac.33.7.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gu J. W., Neu H. C. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics. Antimicrob Agents Chemother. 1990 Feb;34(2):189–195. doi: 10.1128/aac.34.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones P., Bodey G. P., Rolston K., Fainstein V., Riccardi S. Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patients. Am J Med. 1988 Jul 25;85(1A):3–8. doi: 10.1016/0002-9343(88)90168-4. [DOI] [PubMed] [Google Scholar]
  9. Jones R. N., Barry A. L., Thornsberry C. Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob Agents Chemother. 1989 Jun;33(6):944–950. doi: 10.1128/aac.33.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Karp J. E., Merz W. G., Hendricksen C., Laughon B., Redden T., Bamberger B. J., Bartlett J. G., Saral R., Burke P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. doi: 10.7326/0003-4819-106-1-1. [DOI] [PubMed] [Google Scholar]
  11. Meunier F., Zinner S. H., Gaya H., Calandra T., Viscoli C., Klastersky J., Glauser M. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May;35(5):873–878. doi: 10.1128/aac.35.5.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Piccart M., Klastersky J., Meunier F., Lagast H., Van Laethem Y., Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870–875. doi: 10.1128/aac.26.6.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  14. Rolston K. V., Nguyen H., Messer M., LeBlanc B., Ho D. H., Bodey G. P. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother. 1990 Nov;34(11):2263–2266. doi: 10.1128/aac.34.11.2263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Viscoli C., Van der Auwera P., Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother. 1988 Apr;21 (Suppl 100):149–156. doi: 10.1093/jac/21.suppl_c.149. [DOI] [PubMed] [Google Scholar]
  16. Winston D. J., Ho W. G., Nakao S. L., Gale R. P., Champlin R. E. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1986 May;80(5):884–890. doi: 10.1016/0002-9343(86)90633-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES